Clinical Trial Update: Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating tailored prednisone reduction to prevent hyperglycemia in patients with B-cell non-Hodgkin lymphoma undergoing combination chemo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• PREDNISONE (Prednisone)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING